Laboratory Co. of America - LH Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LH shares.
View LH analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1 year price targets for Laboratory Co. of America's stock. Their LH share price forecasts range from $260.00 to $303.00. On average, they predict the company's share price to reach $283.50 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for LH or view top-rated stocks among Wall Street analysts.

Laboratory Co. of America's stock was trading at $235.48 at the start of the year. Since then, LH shares have decreased by 9.4% and is now trading at $213.32.
View the best growth stocks for 2023 here.

Laboratory Co. of America saw a increase in short interest in February. As of February 28th, there was short interest totaling 1,640,000 shares, an increase of 13.1% from the February 13th total of 1,450,000 shares. Based on an average daily trading volume, of 631,700 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.9% of the company's stock are sold short.
View Laboratory Co. of America's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our LH earnings forecast.

Laboratory Co. of America Holdings (NYSE:LH) issued its quarterly earnings results on Thursday, February, 16th. The medical research company reported $4.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.08. The medical research company earned $3.67 billion during the quarter, compared to the consensus estimate of $3.74 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 17.68% and a net margin of 8.60%. The company's revenue for the quarter was down 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.77 EPS.
Read the conference call transcript.

Laboratory Co. of America announced a quarterly dividend on Thursday, January 12th. Stockholders of record on Thursday, February 23rd will be given a dividend of $0.72 per share on Monday, March 13th. This represents a $2.88 annualized dividend and a dividend yield of 1.35%. The ex-dividend date is Wednesday, February 22nd.
Read our dividend analysis for LH.

ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include iShares U.S. Healthcare Providers ETF (IHF), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Telemedicine & Digital Health ETF (EDOC), VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Health Care AlphaDEX Fund (FXH), SEI Enhanced U.S. Large Cap Value Factor ETF (SEIV), Schwab Ariel ESG ETF (SAEF) and BrandywineGLOBALDynamic US Large Cap Value ETF (DVAL).

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.31%. The dividend payout ratio is 20.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 15.34% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

Laboratory Co. of America issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided EPS guidance of $16.00-$18.00 for the period, compared to the consensus earnings per share estimate of $17.65. The company issued revenue guidance of $15.03 billion-$15.47 billion, compared to the consensus revenue estimate of $15.01 billion.

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

Laboratory Co. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Laboratory Co. of America's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (2.05%), Bank of America Corp DE (1.75%), Lazard Asset Management LLC (1.73%), Dimensional Fund Advisors LP (1.65%), Morgan Stanley (1.49%) and Norges Bank (1.05%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends.

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LH stock can currently be purchased for approximately $213.32.

Laboratory Co. of America (NYSE:LH) has a market capitalization of $18.88 billion and generates $14.88 billion in revenue each year. The medical research company earns $1.28 billion in net income (profit) each year or $13.86 on an earnings per share basis.

The company employs 80,000 workers across the globe.

Laboratory Co. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The official website for the company is www.labcorp.com. The medical research company can be reached via phone at (336) 229-1127, via email at investor@labcorp.com, or via fax at 336-513-4510.